Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation

Pediatric Critical Care Medicine

Volumn 13, Issue 6, 2012, Pages

  Maul, Timothy M ^a,b,c   Wolff, Erin L ^a,b,c   Kuch, Bradley A ^a   Rosendorff, Adam ^a   Morell, Victor O ^a   Wearden, Peter D ^a,c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b University of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

anticoagulation; blood; extracorporeal membrane oxygenation; pediatric

Indexed keywords

ANTITHROMBIN III; FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN; THROMBATE; UNCLASSIFIED DRUG;

ADOLESCENT; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CHILD; CLINICAL LABORATORY; DRUG DOSE TITRATION; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; HEART FAILURE; HEMATOLOGICAL PARAMETERS; HEMOFILTRATION; HUMAN; INFANT; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL DEVICE; NEWBORN; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; POINT OF CARE TESTING; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; EXTRACORPOREAL MEMBRANE OXYGENATION; HEART FAILURE; HEMORRHAGE; HEPARIN; HUMANS; INFANT; PARTIAL THROMBOPLASTIN TIME; POINT-OF-CARE SYSTEMS; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; WHOLE BLOOD COAGULATION TIME;

EID: 84869885689     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e31825b582e     Document Type: Article

References (33)

1. Extra Corporeal Life Support Organization: ECLS Registry Report. Ann Arbor, MI, 2009
2. Lequier L: Extracorporeal life support in pediatric and neonatal critical care: A review. J Intensive Care Med 2004; 19:243-258
3. Desai UR, Petitou M, Björk I, et al: Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J Biol Chem 1998; 273:7478-7487 (Pubitemid 28152771)
4. Estes JW: Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5:204-220
5. Monagle P, Chan A, Massicotte P, et al: Antithrombotic therapy in children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl 3):645S-687S (Pubitemid 39297967)
6. Carberry KE, Gunter KS, Gemmato CJ, et al: Mechanical circulatory support for the pediatric patient. Crit Care Nurs Q 2007; 30:121-142 (Pubitemid 351338882)
7. Chan AK, Leaker M, Burrows FA, et al: Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997; 77:270-277 (Pubitemid 27084914)
8. Baird CW, Zurakowski D, Robinson B, et al: Anticoagulation and pediatric extracorporeal membrane oxygenation: Impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007; 83:912-919; discussion 919-920
9. Smythe MA, Koerber JM, Nowak SN, et al: Correlation between activated clotting time and activated partial thromboplastin times. Ann Pharmacother 2002; 36:7-11 (Pubitemid 34052936)
10. Nankervis CA, Preston TJ, Dysart KC, et al: Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007; 53:111-114 (Pubitemid 46145500)
11. Reiner JS, Coyne KS, Lundergan CF, et al: Bedside monitoring of heparin therapy: Comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 1994; 32:49-52 (Pubitemid 24125424)
12. Dauchot PJ, Berzina-Moettus L, Rabinovitch A, et al: Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass. Anesth Analg 1983; 62:710-719 (Pubitemid 13027125)
13. Bain B, Forster T, Sleigh B: Heparin and the activated partial thromboplastin time-a difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Pathol 1980; 74:668-673 (Pubitemid 11241035)
14. Kuhle S, Eulmesekian P, Kavanagh B, et al: Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 2007; 92:554-557 (Pubitemid 350144302)
15. Andrew M, Paes B, Milner R, et al: Development of the human coagulation system in the full-term infant. Blood 1987; 70:165-172 (Pubitemid 17111257)
16. Smythe MA, Caffee A: Anticoagulation monitoring. J Pharm Practice 2004; 17:317-326 (Pubitemid 39658288)
17. Kim GG, El Rouby S, Thompson J, et al: Monitoring unfractionated heparin in pediatric patients with congenital heart disease having cardiac catheterization or cardiac surgery. J Thromb Thrombolysis 2010; 29:429-436
18. Fortenberry JD, Bhardwaj V, Niemer P, et al: Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation. J Pediatr 1996; 128(5 Pt 1):670-678 (Pubitemid 26137726)
19. Peek GJ, Firmin RK: The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. ASAIO J 1999; 45:250-263 (Pubitemid 30116981)
20. Cheng H, Yan R, Li S, et al: Shear-induced interaction of platelets with von Willebrand factor results in glycoprotein Ibalpha shedding. Am J Physiol Heart Circ Physiol 2009; 297:H2128-H2135
21. Straub A, Wendel HP, Dietz K, et al: Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Thromb Haemost 2008; 99:609-615 (Pubitemid 351549299)
22. Rosenthal P: Assessing liver function and hyperbilirubinemia in the newborn. National Academy of Clinical Biochemistry. Clin Chem 1997; 43:228-234 (Pubitemid 27024421)
23. Rosner B: Regression correlation methods. In: Fundamentals of Biostatistics. Crockett C (Ed). Pacific Grove, CA, Duxbury, 2000, p 770
24. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310 (Pubitemid 16134762)
25. Ferring M, Reber G, de Moerloose P, et al: Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients. Can J Anaesth 2001; 48:1155-1160 (Pubitemid 34223654)
26. Egorina EM, Sovershaev MA, Hansen JB: The role of tissue factor in systemic inflammatory response syndrome. Blood Coagul Fibrinolysis 2011; 22:451-456
27. Levi M, van derPoll T, Schultz M: Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunol 2012; 34:167-179
28. Atkins BZ, Danielson DS, Fitzpatrick CM, et al: Modified ultrafiltration attenuates pulmonary-derived inflammatory mediators in response to cardiopulmonary bypass. Interact Cardiovasc Thorac Surg 2010; 11:599-603
29. Michelson AD: Platelet function in the newborn. Semin Thromb Hemost 1998; 24:507-512 (Pubitemid 29095423)
30. Oliver WC: Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13:154-175
31. Kanji HD, Schulze CJ, Oreopoulos A, et al: Peripheral versus central cannulation for extracorporeal membrane oxygenation: A comparison of limb ischemia and transfusion requirements. Thorac Cardiovasc Surg 2010; 58:459,462
32. Eikelboom JW, Hirsh J: Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thromb Haemost 2006; 96:547-552 (Pubitemid 44782532)
33. Koerber JM, Smythe MA, Begle RL, et al: Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy 1999; 19:922-931 (Pubitemid 29377310)